Published study by CHEAR Faculty and Staff featured in Immunization Economics Community of Practice
August 1, 2023
A recent study by Kim DeLuca et al. (2023) found that influenza vaccination is economically attractive for most age and risk groups. The cost-effectiveness of influenza vaccination was found to be less than $95,000 per quality-adjusted life year for all subgroups, except for non-high-risk working-age adults. Vaccination of healthy adults aged 18-49 years may exceed common cost-effectiveness thresholds, while vaccination for higher risk subgroups remains below common cost-effectiveness thresholds even at low levels of vaccine effectiveness or circulating virus. Results were most sensitive to changes in the probability of influenza illness.
Collaborators: Kim DeLuca E, Gebremariam A, Rose A, Biggerstaff M, Meltzer MI, Prosser LA